Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
Petra Petranović Ovčariček, Alfredo Campennì, Bart de Keizer, Désirèe Deandreis, Michael C. Kreißl, Alexis Vrachimis, Murat Tuncel, Luca Giovanella
Abstract
Differentiated thyroid cancer (DTC) is the most common subtype of thyroid cancer and has an excellent overall prognosis. However, metastatic DTC in certain cases may have a poor prognosis as it becomes radioiodine-refractory. Molecular imaging is essential for disease evaluation and further management. The most commonly used tracers are [18F]FDG and isotopes of radioiodine. Several other radiopharmaceuticals may be used as well, with different diagnostic performances. This review article aims to summarize radiopharmaceuticals used in patients with radioiodine-refractory DTC (RAI-R DTC), focusing on their different molecular pathways. Additionally, it will demonstrate possible applications of the theranostics approach to this subgroup of metastatic DTC.